中国临床药学杂志

参考文献

1朱明德 .临床治疗学 (上 ) .上海 :上海科学技术出版社 ,1994:876

2 Scheen AJ,Lefebure PJ. Pathophysiology of Type 2 diabetes. In:Kuhlmann J,Puls W,editors. Handbook of experimentalpharmacology:oral antidiabetics. Berlins:Spinger Verlag,1995 :7～ 42

3 Melander A,Bitzen PO,Faber O,et al. Sulphonylureaantidiabetic drugs:an update of their clinical pharmacology andrational therapeutic use. Drugs,1989,3 7:5 8

4Groop L C.Sulfonylureas and NIDDM.Diabetes Carem,1992 ,15 :73 7

5 Lebouitz HE,Melander A. Sulfonylureas:basic aspects andclinical uses. In:Alberti KGMM,De Fronzo Ra,Keen H,et al.Editors.International texbook of diabetes mellitus.Chichester:JWiley,1992 :745

6征革凡 ,王金平 ,张辉 ,等 .拜糖平治疗非胰岛素依赖型糖尿病的临床观察 .中华内分泌代谢杂志 ,1995 ,11( 3 ) :163

7Nolan JJ,L uduik B,Beerdsen P,et al.Improvement in glucosetolerance and insulin resistance in obese subjects treated withtroglitazone.N Eng JMed,1994,3 3 1:1188

8Kumar S,Boulton AJM,Beck-Nielsen H,etal. Troglitazone,aninsulin action enhancer,improves metabolic control in NIDDMpatients. Diabetologia,1996,3 9:70 1

9Mimura K,Umeda F,Hiramatsu S,et al.Effects of a new oralhypoglycaemic agent ( CS-0 45 ) on metabolic abnorm alities andinsulin resistance in type 2 diabetes. Diabetic Med,1994,11:685

10 Fontbonne A,Charles MA,Juhan-Vague L ,et al. The effectofmetformin on the metabolic abnormalities associated with upper-body fat distribution.Diabetes Care,1996,19:92 0

11Nagi DK,Yudkin JS. Effects of metformin on insulin resistance,risk factors for cardiovascular disease,and plasminogen activatorinhibitor in NIDDM subjects.Diabetes Care,1993 ,16:62 1

12高妍 ,冯晋光 ,李长红 ,等 .拜糖平和美迪康对 2型糖尿病降糖作用的临床疗效比较 .中华内分泌代谢杂志 ,1998,14 ( 1) :8

13 Hermann L s,Schersten B,Bitzen PO,et al. Therapeuticcomparison of metformin and sulfonylurea,alone and in variouscombinations:a double-blind controlled study.Diabetes Care,1994,17:110 0

14 Hermann LS. Biguanides and sulfonylureas as conbinationtherapy in NIDDM.Diabetes Care,1990 ,13 ( Supple3 ) :3 7

15 Chiasson JL,Josse RG,Hunt JA,etal.The efficacy of acarbosein the treatment of patients with non-insulin-dependent diabetesmellitus:a multicenter controlled clinical trial. Ann Intern Med,1994,12 1:92 8

16Hanefeld M,Bar K,Mertes G,et al.Metformin improvesmetabolic control in non-insulin-dependent diabetics withacarbose monotherapy. Diabetologia,1997,40 ( Suppl 1) :A3 12

17Iwamoto Y,Kosaka K,Kuzuya T,et al.Effect of combinationtherapy of troglitazone and sulphonylureas in patients with type2diabetes who were poorly controlled by sulphonylurea therapyalone. Diabetic Med,1996,13 :3 65

18Insucchi SE,Maggs DG,Spollett GR,et al.Efficacy andmetabolic effects of troglitazone and metformin in NIDDM.Diabetes,1997,46( Suppl 1) :3 4 A

19Giugliano D,Quatraro A,Consoli G,et al. Metformin forobese,insulin-treated diabetic patients:improvements inglycaemic control and reduction of metabolic risk factors.Eur JClin Pharmacol,1993 ,44:10 7

2 0 Hotta N,Kakuta H,Koh N,et al. The effects of acarbose onblood glucose profiles of type2 diabetic patients receiving insulintherapy.Diabetic Med,1993 ,10 :3 5 5

2 1Coniff RF ,Shapiro JA,Seaton TB,et al. A double-blindplacebo-controlled trial evaluating the safety and efficacy ofacarbose for the treatment of patients with insulin-requiring type diabetes.Diabetes Care,1995 ,18:92 8

2 2 L ebovitz HE. Oralantidiabetic drugs:the emergence of alphaglucosidase inhibitors. Drugs,1992 ,44( Suppl 3 ) :2 1